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Our understanding of how the endoplasmic reticulum (ER)-associated
protein degradation (ERAD) machinery efficiently targets terminally
misfolded proteins while avoiding the misidentification of nascent
polypeptides and correctly folded proteins is limited. For luminal
N-glycoproteins, demannosylation of their N-glycan to expose a
terminal α1,6-linked mannose is necessary for their degradation via
ERAD, but whether this modification is specific to misfolded proteins
is unknown. Here we report that the complex of the mannosidase
Htm1p and the protein disulfide isomerase Pdi1p (Htm1p–Pdi1p) acts
as a folding-sensitive mannosidase for catalyzing this first committed
step in Saccharomyces cerevisiae. We reconstitute this step in vitro
with Htm1p–Pdi1p and model glycoprotein substrates whose struc-
tural states we can manipulate. We find that Htm1p–Pdi1p is a
glycoprotein-specific mannosidase that preferentially targets nonna-
tive glycoproteins trapped in partially structured states. As such,
Htm1p–Pdi1p is suited to act as a licensing factor that monitors fold-
ing in the ER lumen and preferentially commits glycoproteins trapped
in partially structured states for degradation.
ERAD | ER quality control | mannosidase | N-glycoprotein
Proteins destined for the secretory pathway enter the endoplas-mic reticulum (ER) in unfolded states and generally leave only
after they have reached their native conformation. Protein folding
in the ER is challenging and often error-prone (1, 2). Thus, the ER
must continuously monitor the pool of folding proteins and remove
terminally misfolded forms before they induce toxicity. This removal
is accomplished through a series of pathways collectively referred
to as the “ER-associated protein degradation” (ERAD) machinery
(3). Generally, the process of ERAD involves three steps:
(i) identification of the misfolded protein, (ii) retrotranslocation
and polyubiquitination of the misfolded protein through individual
E3 ubiquitin ligase complexes, and (iii) degradation of the mis-
folded protein by the ubiquitin–proteasome system in the cytosol.
Each ERAD pathway needs to identify substrates accurately to
avoid overly promiscuous destruction of functional proteins while
preventing the accumulation of toxic forms (1). For the ERAD
pathway responsible for the destruction of proteins with misfolded
luminal domains (ERAD-L) (4, 5), this process of discrimination
depends not only on the folding status of a polypeptide but also on
its N-glycosylation state (6–11). Upon entering the ER lumen, na-
scent proteins acquire en bloc a high-mannose oligosaccharide,
Glc3Man9GlcNAc2, appended to a specific subset of asparagine
residues (Fig. 1A). The N-glycan then is deconstructed mono-
saccharide-by-monosaccharide to Man8GlcNAc2 (Man8) in the ER
by a series of glycosidases concurrently with the protein-folding
process (12, 13). The action of the mannosidase Mns1p, which is
responsible for generating Man8, has been proposed to yield a
“timer” that universally gives all N-glycoproteins a defined period to
fold during which they are immune from ERAD-L (8, 12). Mis-
folded proteins that are destined for degradation via ERAD-L are
further demannosylated by Htm1p (also known as Mnl1p), which
removes the α1,2-linked mannose from the C branch of Man8 (14,
15). The resulting Man7GlcNAc2 (Man7) glycan structure with a
terminally exposed α1,6-linkedmannose serves as a signal for ERAD-L
commitment. The Yos9p lectin subsequently binds this terminally
exposed α1,6-linked mannose and, in coordination with Hrd3p,
queries the misfolded regions on potential substrates (6, 7, 9–11, 16).
Only the presence of both the Htm1p-generated N-glycan signal
and the misfolded regions on the substrate enables Yos9p–Hrd3p
to trigger the downstream retrotranslocation, polyubiquitination, and
proteasomal degradation of target proteins (7, 14, 17). The physio-
logical importance of these checkpoints is exemplified by the severe
growth defect acquired when the requirement for Hrd3p and Yos9p
was bypassed by overexpression of HRD1, which encodes the down-
stream E3 ubiquitin ligase for this pathway (6).
As the first committed step, the generation of the terminally
exposed α1,6-linked mannose by Htm1p has the potential to de-
termine which proteins are shunted down the ERAD-L pathway
and the stage during their folding process when this shunting occurs.
This potential “licensing” role has been supported by in vivo ob-
servations that genetic deletion ofHTM1, as well as point mutations
in its putative active sites, not only retards the degradation of
misfolded N-glycoproteins but also decreases substrate-binding by
Yos9p (11, 14, 17–19). This retardation of ERAD by the deletion of
HTM1 can be circumvented in a genetic background that generates
the terminally exposed α1,6-linked mannose (7). The importance of
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the mannosidase function of Htm1p is further evidenced by the
conserved role of HTM1 homologs for the N-glycan–dependent
ERAD pathway (20–22). Finally, both in vivo and in vitro studies
have provided evidence for the mannosidase activity of Htm1p in
generatingMan7 (14, 15, 23). However, despite the well-documented
role of Htm1p in the N-glycan processing for ERAD-L commitment,
it is still unclear whether Htm1p targets misfolded proteins specifi-
cally and accurately. This uncertainty mainly results from the chal-
lenges in simultaneously monitoring protein conformations and their
N-glycosylation states in the highly heterogeneous pool of glyco-
proteins in the ER. Additionally, only minimal mannosidase activities
of Htm1p were observed in previous in vitro studies (15, 23). To
advance our understanding of this commitment step, it is critical to
develop a reconstituted system for direct investigation of the enzy-
matic activities of Htm1p against glycoproteins with defined glyco-
sylation and folding states (24).
Here, we reconstituted this ERAD-L commitment step, which
consists of a recombinantly expressed Htm1p–Pdi1p complex and
glycoprotein substrates with various native and nonnative confor-
mations. Our results reveal that Htm1p–Pdi1p is a glycoprotein-
specific mannosidase complex that preferentially demannosylates
intrinsically or artificially misfolded proteins but not their native
counterparts. Furthermore, among the various nonnative confor-
mations, Htm1p–Pdi1p prefers partially structured proteins over
globally unfolded ones. Our findings suggest that Htm1p–Pdi1p
monitors the protein-folding states in the ER lumen and preferen-
tially licenses glycoproteins trapped in partially structured states
for ERAD-L.
Results
Generation of Man7 in Vivo Is Folding- and HTM1-Dependent. It has
been reported that the prototypic ERAD-L substrate CPY* con-
tains higher levels of Man7 than its folding-competent counterpart,
procarboxypeptidase Y (CPY) in a wild-type yeast background (11).
We first explored whether the higher level of Man7 in CPY* reflects
the differences in intrinsic folding competence between CPY* and
CPY or instead results passively from the prolonged ER retention of
CPY*. Using a previously described overexpression construct (25),
we expressed and purified native CPY and CPY* that are retained
in the ER by a C-terminal HDEL tag. We used MALDI-TOF MS
to determine the glycan profile of CPY and CPY*. This approach
provides higher throughput capacity than HPLC-based measure-
ment while still allowing quantitative analysis of neutral glycans (26).
As such, it also is amenable to the analysis of mannosidase activities
described below. Both CPY and CPY* purified from a wild-type
yeast strain (BY4741) carried predominantly Man8 and minor
populations of Man7, Man9, and Hex10GlcNAc2 (Hex10), which is
likely GlcMan9GlcNAc2 (Fig. S1). The majority of the signal of
Man7 disappeared when CPY and CPY* were purified from the
htm1Δ strain background (Fig. 1 B and C). When CPY and CPY*
were purified from an mns1Δhtm1Δ background, the dominant
glycan species shifted fromMan8 to Man9, further verifying that the
majority of Man8 from the wild-type strain is the product of Mns1p,
the putative substrate of Htm1p (Fig. S1). Importantly, CPY* car-
ried a significantly higher level of Man7 than CPY (Fig. 1 B and C).
Taken together, these observations suggest that, although both are
retained in the ER, CPY* and CPY are differentially demannosy-
lated to Man7 in an HTM1-dependent manner. Because CPY and
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Fig. 1. HTM1mediates N-glycan processing for ERAD-L commitment. (A) Scheme of N-glycan processing and ERAD-L commitment. Upon entering the ER, nascent
N-glycoproteins acquire Glc3Man9GlcNAc2 en bloc, which is step-by-step deglycosylated as the nascent polypeptide folds. Mns1p catalyzes the last universal
deglycosylation step to generate the Man8GlcNAc2 glycan. Native proteins are targeted for the downstream secretory pathway, and misfolded proteins are tar-
geted by Htm1p, which removes the α1,2-linked mannose at the C branch from the Man8GlcNAc2 glycan. The resulting terminally exposed α1,6-linked mannose
and misfolded regions on the polypeptide chain are then read by Yos9p. Along with Hrd3p, Yos9p then permits the downstream retrotranslocation and poly-
ubiquitination through the Hrd1p transmembrane complex for eventual proteasomal degradation. (B) Examples of glycan profiles of CPY and CPY* expressed in
wild type (WT) or htm1Δ yeast strains as measured by MALDI-TOF MS after the glycans were released from CPY/CPY* by PNGase F treatment. Each glycan was
assigned to the m/z corresponding to its predicted [M+Na]+ value. (C) The relative abundance of Man7 is higher in CPY* than in CPY in wild-type yeast, which is
dependent on HTM1. The relative MS peak intensity of Man7, as found in B, is normalized to the total of Man7 and Man8 as a proxy for its relative abundance.
Shown are the mean values ± one SD from biological triplicates. The P value was calculated by unpaired t test.
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CPY* purified through this HDEL-tagged system are different only
at the G255R point mutation on CPY* that disrupts the hydro-
phobic core on the native structure (27), we conclude that the
generation of Man7 in the ER is correlated with the intrinsic folding
competence of the underlying protein.
Reconstitution of an Htm1p–Pdi1p Complex. To explore the activity
of Htm1p in vitro, we tested the feasibility of producing Htm1p
from the native host Saccharomyces cerevisiae. We introduced a
3xFLAG tag, followed by an HDEL tail before the stop codon, to
the C terminus of Htm1p for affinity purification. The result of the
cycloheximide degradation assay on CPY* suggests that the chro-
mosomally tagged version is similarly functional to wild-type Htm1p
(Fig. 2A). Because the endogenous level of Htm1p is low, we en-
hanced the expression of Htm1p by chromosomally substituting its
endogenous promoter with a TDH3 promoter (Fig. 2B). Consistent
with findings in a previous study (28), Htm1p readily formed a
disulfide complex with endogenous Pdi1p as resolved by non-
reducing SDS/PAGE (Fig. 2B). Large-scale immunoprecipitation
yielded an Htm1p–Pdi1p complex with nearly 1:1 stoichiometry
(Fig. 2C), with a yield of 200 μg of the complex from 3 L of yeast
culture. Treatment of the complex with endoglycosidase H con-
firmed that both Htm1p and Pdi1p were N-glycosylated, indicating
that they are correctly targeted to the secretory pathway (Fig. 2D).
The complex behaved as a monodisperse species in size-exclusion
column chromatography (Fig. 2E), which contained a mixture of
both disulfide-linked and noncovalent complexes of Htm1p and
Pdi1p (Fig. 2F). We did not detect any monomeric Htm1p or Pdi1p
corresponding to their predicted mass (90.2 kDa for Htm1p and
56.0 kDa for Pdi1p). Finally, we observed the mannosidase activity
against the most preferred glycoprotein substrate, RBsp (RNase BS
protein with the N-terminal S peptide removed), only in the frac-
tions containing the Htm1–Pdi1p complex (Fig. 2G and see below).
Htm1p–Pdi1p Preferentially Demannosylates CPY* and Misfolded CPY
Variants.We first explored the mannosidase activity of reconstituted
Htm1p–Pdi1p on CPY and CPY* that we purified from wild-type
yeast. After a 20-h reaction, Htm1p–Pdi1p converted a portion of
Man8 on CPY and CPY* to Man7 (Fig. 3 A and B). Consistent with
our in vivo observation, the increase in Man7 is significantly higher
on CPY* than on CPY after incubation with Htm1p–Pdi1p (Fig.
3C). For further validation that Htm1p–Pdi1p preferentially targets
nonnative proteins, we reductively denatured CPY to remove its
structurally essential disulfide bonds (29). Reduced CPY then was
either oxidized under denaturing condition into “scrambled” species
with randomly distributed nonnative disulfide bonds (Scr-CPY) or
carbamidomethylated to block the reformation of disulfide bonds
(Carb-CPY). Htm1p–Pdi1p also demannosylated both Scr-CPY
and Carb-CPY more efficiently than the native form, and the yield
of Man7 was higher on Scr-CPY than on Carb-CPY (Fig. 3D).
Taken together, these results suggest that our reconstituted Htm1p–
Pdi1p is an active mannosidase and acts preferentially on in-
trinsically folding-incompetent CPY* and on artificially misfolded
CPY variants rather than on the native CPY.
We then wanted to verify whether demannosylation is catalyzed
through the predicted mannosidase domain of Htm1p and whether
Pdi1p is required for this process. We carried out the reaction in the
presence of EDTA, which sequesters the structurally essential Ca2+,
and 1-deoxymannojirimycin (DMJ), which inhibits the GH47 man-
nosidase family to which Htm1p is predicted to belong (30). Both
chemicals inhibited the generation of Man7 on CPY* (Fig. 3E). We
further verified the predicted mannosidase function of Htm1p with
an Htm1 mutant in which one of the putative active site residues,
A
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Fig. 2. Recombinant preparation of Htm1–Pdi1p from S. cerevisiae. (A) The percentage of HA-tagged CPY* remaining in wild-type BY4741 (WT), htm1Δ, and
chromosomally 3xFLAG–HDEL–taggedHTM1 (HTM1-3xFLAG) normalized to time 0 along the time course after the addition of cycloheximide. Shown are the mean
values ± one SEM measured by quantitative Western blot from four biological replicates. (B) Expression levels of Htm1p–3xFLAG driven by either the endogenous
HTM1 promoter (pHTM1) or the chromosomally inserted TDH3 promoter (pTDH3) as visualized by Western blot against FLAG-tagged Htm1p and Pdi1p after
nonreducing SDS/PAGE separation of the same amount of cell pellets. (C) Specific interaction between Htm1p and Pdi1p after immunoprecipitation with anti-FLAG
affinity resin followed by TEV protease treatment to release FLAG-tagged Htm1p. Shown is a Coomassie Blue R250-stained gel image after separation by reducing
SDS/PAGE. (D) The N-glycosylation states of Htm1p and Pdi1p as checked by endoglycosidase H (Endo H). (E) Superdex 200 10/300GL size-exclusion column
chromatography of Htm1p–Pdi1p eluted from anti-FLAG resin by 3xFLAG peptide. (F) Western blot analysis of the distribution of Htm1p–3xFLAG and Pdi1p after
nonreducing SDS/PAGE of the fractions separated by the size-exclusion column chromatography. (G) The relative abundance of Man7 in the total of Man7 and
Man8 on RBsp after 1-h incubation with the fractions collected from the size-exclusion column chromatography of purified Htm1p–Pdi1p.
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Glu222, is mutated to Gln (E222Q) (14, 31). This mutant indeed was
incapable of generating Man7 on CPY* (Fig. 3E). Finally, we made
a second Htm1 mutant with a truncation of the amino acyl region
from residue 572 to residue 657 (Δ572–657), which covers the re-
gion necessary for interaction with Pdi1p (Fig. S2A) (14, 23, 28).
Immunoprecipitation confirmed that Δ572–657 showed little de-
tectable interaction with Pdi1p (Fig. S2B). Similar to the catalytically
dead E222Q, Δ572–657 was incapable of generating Man7 on
CPY* (Fig. 3E). Collectively, our results support the notion that the
predicted mannosidase domain of Htm1p mediates the demanno-
sylation reaction and that the interaction with Pdi1p is required for
this activity.
The conversion of Man8 to Man7 on CPY* continued during
prolonged incubation with Htm1p–Pdi1p (Fig. S3A), but this rate
of demannosylation is nonetheless much slower than would be
expected from the in vivo half-life of CPY*, which is about 60 min
(Fig. 2A). This slow rate could, in principle, be a consequence of
CPY having four N-glycans, and thus Htm1p–Pdi1p may act on
only a subset of the glycans on CPY*. Indeed, the C-terminal–most
N-glycan of CPY* is known to be necessary and sufficient to
support its ERAD in vivo (17, 32, 33). However, we found that in
vitro Htm1p–Pdi1p demannosylated a CPY* mutant (CPY*1110),
in which this ERAD-competent glycosylation site, Asn479, was
mutated to Gln, to a level similar to CPY* with all four glycosyl-
ation sites (Fig. S3B). A similar level of demannosylation was ob-
served on another CPY* mutant (CPY*0001), in which the other
three glycosylation sites (Asn124, Asn198, and Asn279) were all
mutated to Gln. The glycosylation site thus is not likely to be the
key factor limiting the catalytic activity. Increasing the amount of
Htm1p–Pdi1p by fourfold did not increase the yield proportionally,
suggesting that the enzyme concentration also is not the major
limiting factor (Fig. S3E).
The incomplete reaction may reflect conformational heteroge-
neity or the aggregation-prone nature of CPY*. Indeed, in our
hands, the majority of purified CPY* is in oligomeric forms (Fig.
S4), and we observed the formation of visible aggregates from both
CPY* and artificially misfolded CPY variants after incubation with
Htm1p–Pdi1p for 20 h. A potential consequence of aggregation is
that the glycans become inaccessible to the deep active pocket of
Htm1p as predicted by the GH47 family mannosidase domain (34).
We first explored whether Htm1p–Pdi1p has higher activity against
the free Man8 glycan. Htm1p–Pdi1p generated only a limited
amount of Man7 after 24 h of reaction (Fig. S5A). In contrast,
Mns1p, which similarly contains a GH47 family mannosidase do-
main, was able to demannosylate Man9 into Man8 completely (Fig.
S5B). Then, to assess the accessibility to glycans on CPY, we tested
the activity of Mns1p against Man9-carrying CPY (CPYm9) and its
scrambled form (Scr-CPYm9) purified from the mns1Δhtm1Δ
strain background. Mns1p converted most of Man9 on both
CPYm9 and Scr-CPYm9 into Man8, suggesting that the glycans are
accessible on both native and nonnative forms of CPY (Fig. 4).
Mns1p alone did not produce any detectable Man7. Only
cotreatment of Mns1p and Htm1p–Pdi1p yielded Man7 at a level
similar to that we observed in Fig. 3. We found that Htm1p–
Pdi1p alone, without Mns1p, also was capable of demannosy-
lating Man9 on CPYm9 and Scr-CPYm9 into Man8, albeit to a
lower extent. Similar to the results in Fig. 3D, the level of Man8
generated by Htm1p–Pdi1p treatment was higher on Scr-CPYm9
than on CPYm9. Collectively, these observations suggest in-
trinsic differences in substrate specificity between Mns1p and
Htm1p–Pdi1p: Although Mns1p is capable of targeting both free
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80
100
1550 1675 1800
Mass (m/z)
0
40
20
60
%
 re
la
tiv
e 
in
te
ns
ity
20 hr
Ctrl
CPY
Man8Man7
80
100
0
40
20
60
%
 re
la
tiv
e 
in
te
ns
ity
20 hr
Ctrl
1550 1675 1800
Mass (m/z)
CPY*
A
0 
0.05 
0.1 
0.15 
0.2 
0.25 
CPY CPY*
C
ha
ng
e 
of
 re
la
tiv
e 
ab
un
da
nc
e 
of
 M
an
7
to
 th
e 
to
ta
l o
f M
an
8 
an
d 
M
an
7
p=0.0117
C
B
D
p=0.0183
p=0.0028
0 
0.04 
0.08 
0.12 
0.16 
CPY Scr-CPY Carb-CPY 
C
ha
ng
e 
of
 re
la
tiv
e 
ab
un
da
nc
e 
of
 M
an
7
to
 th
e 
to
ta
l o
f M
an
8 
an
d 
M
an
7
W
T
+EDTA 
+DMJ 
E222Q 
∆572-657 
-0.06 
-0.03 
0 
0.03 
0.06 
0.09 
0.12 
0.15 
C
ha
ng
e 
of
 re
la
tiv
e 
ab
un
da
nc
e 
of
 M
an
7
to
 th
e 
to
ta
l o
f M
an
8 
an
d 
M
an
7
E
Fig. 3. Htm1p–Pdi1p preferentially demannosylates CPY* and nonnative CPY variants. (A and B) Representative glycan profiles of CPY (A) and CPY* (B) before and
after 20-h incubation with Htm1p–Pdi1p. CPY or CPY* (2 μM) was incubated with 0.1 μM Htm1p–Pdi1p at 30 °C for 20 h and then was separated from Htm1–Pdi1p
by SDS/PAGE for subsequent in-gel glycan release and MALDI-TOF MS analysis. (C) Htm1p–Pdi1p generates more Man7 on CPY* than on CPY after reaction. The
mannosidase activity is measured by the change in the relative abundance of Man7 on CPY and CPY* after 20-h incubation with Htm1p–Pdi1p. Shown are the mean
values ± one SD from an experiment performed in triplicate. The P value was calculated by unpaired t test. (D) Htm1p–Pdi1p generated more Man7 on Carb-CPY
and Scr-CPY than on CPY. Shown are the mean values ± one SD from an experiment performed in triplicate. The P value was calculated by unpaired t test. (E) The
mannosidase activity of Htm1p–Pdi1p against CPY* was inhibited by EDTA (+EDTA), 1-deoxymannojirimicin (+DMJ), and mutations including E222Q and Δ572–657.
Quantification was carried out as in C. Shown are the mean values ± one SD from an experiment performed in triplicate.
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glycans and glycoproteins independently of the attached protein
conformations, Htm1p–Pdi1p preferentially targets glycans in-
stalled on nonnative proteins. In addition, as is consistent with
previous in vivo studies (10, 31, 35), our findings suggest that
Htm1p–Pdi1p is capable of bypassing the action of Mns1p to
demannosylate Man9 directly.
Htm1p–Pdi1p Preferentially Demannosylates Partially Structured
RNase B Variants. To this point, our findings support two poten-
tial models describing how Htm1p–Pdi1p generates the α1,6-linked
mannose signal for ERAD-L commitment. In one model, the ca-
talysis by Htm1p–Pdi1p may be intrinsically slow and stochastic, as
previously suggested (15, 23), and unfolding facilitates demanno-
sylation by increasing access to the glycan. Alternatively, Htm1p–
Pdi1p may preferentially target specific folding states of nonnative
proteins, and the aggregation-prone nature of misfolded CPY
variants prevents them from populating in these states in vitro. To
test these two potential models, we introduced bovine pancreatic
ribonuclease B (RNase B) as an alternative substrate. RNase B is
identical to the well-characterized classic protein folding substrate
RNase A protein except that it contains a single N-glycosylation site
(36). The folding of RNase B has been studied extensively, and the
proteins can be manipulated to form well-defined, homogeneous
states of native, misfolded or unfolded conformations (37–39).
Using a concanavalin A (Con A) lectin-based approach (40), we
can enrich for Man8-abundant RNase B from commercial sources
in biochemical quantities (Fig. S6). To generate a nonnative variant
of RNase B, we proteolytically removed the N-terminal S peptide
from native RNase B to produce RBsp (Fig. 5A). RBsp is trapped
in a compact, disordered, but nonetheless well-behaved state, and it
can be readily reconstituted into a native-like RNase BS form by
the addition of the S peptide (38).
Remarkably, Htm1p–Pdi1p differentiated between native RNase
B and RBsp and efficiently demannosylated only RBsp (Fig. 5B).
Demannosylation of Man8 on RBsp into Man7 nearly reached a
plateau after 1 h of incubation with Htm1p–Pdi1p (Fig. S7A). We
further investigated whether Htm1p–Pdi1p can be trans-activated
by RBsp or trans-inhibited by CPY*. We tested these possibilities by
incubating Htm1p–Pdi1p with CPY* for 2 h and then adding RBsp.
Differences in mass between CPY* (76.7 kDa) and RBsp
(13.2 kDa) allow them to be readily separated by SDS/PAGE for
subsequent glycan profiling. No obvious differences were observed
on demannosylation of RBsp in the presence or absence of CPY*,
and vice versa (Fig. S8). We extended this experiment further
with a mixture of native RNase B and RBsp, which, given their
difference in mass, can be similarly separated by SDS/PAGE by the
presence or absence of the S-peptide (Fig. 5C). The presence of
RBsp did not induce the demannosylation of native RNase B by
Htm1p–Pdi1p (Fig. 5D). Collectively, these data establish that
Htm1p–Pdi1p is capable of efficiently demannosylating the specific
type of nonnative proteins to which RBsp belongs and that the ac-
tivity is not trans-regulated in a mixture of different glycoproteins.
Consistent with the results in Fig. 4, we observed the disap-
pearance of Man9 on RBsp during the reaction with Htm1p–Pdi1p
(Fig. S7). The residual Man8 can be attributed to the other two
less-abundant Man8 isoforms on RNase B that already have the
C branch α1,2-mannose removed (41). Indeed, cotreatment with
Mns1p and Htm1p–Pdi1p removed all Man9 and Man8 on RBsp
(Fig. S7B), also verifying that Mns1p and Htm1p–Pdi1p target
different mannoses on Man9. We further explored whether
Htm1p–Pdi1p targets the α1,2-linked mannose on the C branch or
the A branch, a question that never has been thoroughly in-
vestigated. To obtain a structural view of which mannose is re-
moved by Htm1p–Pdi1p, we performed 1H-NMR analysis on the
glycans released from denatured RNase B before and after an
overnight reaction with Htm1p–Pdi1p. Indeed, we found that only
the α1,2-linked mannose on the C branch was removed after
overnight incubation with Htm1p–Pdi1p (Fig. 6), providing struc-
tural evidence to support the existing model in which Htm1p–Pdi1p
specifically removes the α1,2-mannose on the C branch.
To characterize further how accurately Htm1p–Pdi1p differen-
tiates proteins with different nonnative conformations, we gener-
ated three additional variants of RNase B: (i) a subtilisin-nicked
noncovalent complex of RBsp and S-peptide (RNase BS);
(ii) disulfide-scrambled RNase B (Scr-RB); and (iii) cysteine-
carbamidomethylated RNase B (Carb-RB) (Fig. 7A). Consistent
with the known properties of these variants (37, 38), our far-UV
circular dichroism analysis verified that these RNase B variants
cover a range of different conformations (Fig. 7B): RNase BS
behaves essentially identically to native RNase B; RBsp is a
compact folding intermediate with relatively abundant second-
ary structure features; Scr-RB consists of random, less compact
structures with residual signals from secondary structures; and
Carb-RB consists of globally unfolded species with the majority
of the signals from random coils. We further confirmed this
increasing trend of unfolding from native RNase B to Carb-RB
by monitoring the differences in peptide backbone flexibility
and glycan accessibility of different RNase B variants through
trypsin and peptide N-glycanase F (PNGase F) treatment (Fig.
S9 A and B). Of particular note, unlike CPY* and nonnative
CPY variants, both Scr-RB and Carb-RB did not oligomerize or
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Fig. 4. Glycans onmisfolded CPY are accessible for demannosylation. The relative abundance of each glycan on CPYm9 or Scr-CPYm9 after 24-h incubationwithMns1p
and/or Htm1p–Pdi1p or E222Q. Shown are the mean values ± one SD from an experiment performed in triplicate. P values were calculated by unpaired t test.
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aggregate even after overnight incubation with Htm1p–Pdi1p
at 30 °C (Fig. S9 C and D).
Analysis of the demannosylation of RNase B variants by Htm1p–
Pdi1p revealed that Htm1p–Pd1ip was able to distinguish differ-
ences in the conformations of these variants (Fig. 7C). Htm1p–
Pdi1p showed minimal mannosidase activity on the native-like
RNase BS, suggesting that Htm1p–Pdi1p is insensitive to the mild
increase in peptide flexibility around the N-glycosylation site of
RNase BS (42). For nonnative variants, we observed a clear trend
of increasing demannosylation efficiency as one goes from the
globally unfolded Carb-RB to the more compact but heteroge-
neous Scr-RB and finally to the most compact and homogenous
form, RBsp. Demannosylation of Carb-RB continued during pro-
longed incubation (Fig. S10A), suggesting that the lower levels of
demannosylation of Carb-RB at earlier time points resulted from
slower kinetics. The susceptibility of Scr-RBsp and Carb-RBsp to
Htm1p–Pdi1p was similar to that of their full-length counterparts,
suggesting that the difference in the kinetics was not caused by the
absence of the S peptide per se (Fig. S10B). The slower kinetics
against Carb-RB was not caused by alkylation of cysteines, because
a fully reduced RNase B (Red-RB) was demannosylated at a rate
similar to that of Carb-RB (Fig. S10C). In addition, Htm1p–Pdi1p
was not inhibited when its cysteines were first blocked with
iodoacetamide before reaction with RBsp, ruling out the possibility
of a cysteine-mediated demannosylation mechanism (Fig. S10D).
To conclude, our findings demonstrate not only that Htm1p–Pdi1p
differentiates nonnative proteins from native ones but also that it
prefers nonnative proteins with compact, partially structured con-
formations over globally unfolded ones. Our findings support our
second model, in which Htm1p–Pdi1p is a folding-sensitive man-
nosidase and preferentially targets nonnative proteins trapped at
partially structured states.
Discussion
A fundamental question of ERAD is what biochemical properties
differentiate an ERAD substrate from a normal protein in the ER
(3, 43). The unique requirement of an N-glycan remodeling step for
ERAD-L commitment potentially provides a chemical handle for
investigating the biochemical basis that determines an ERAD-L
substrate. This study provides biochemical evidence supporting a
model in which this commitment step by Htm1p–Pdi1p is closely
coordinated with the conformations of potential ERAD-L sub-
strates. As such, the resulting terminally exposed α1,6-linked man-
nose is suitable to be a folding-state mark that flags folding defects
in the attached proteins.
Several lines of biochemical evidence support our conclusion that
Htm1p–Pdi1p is a folding-sensitive mannosidase. First, we see the
mannosidase activity of Htm1p–Pdi1p against misfolded forms of
CPY and RNase B variants but not against free Man8, suggesting
that, unlike Mns1p, Htm1p–Pdi1p is a glycoprotein-specific man-
nosidase. Second, we see a marked enhancement of Htm1p–Pdi1p
demannosylation activity when native CPY and native RNase B are
artificially converted to misfolded forms, suggesting that Htm1p–
Pdi1p prefers the nonnative folding states of proteins to their native
forms. Third, we see significantly higher rates of Htm1p–Pdi1p
activity against partially structured RNase B variants than against
their globally unfolded forms, indicating that Htm1p–Pdi1p can
distinguish different nonnative states. Our biochemical analysis of
the conformational sensitivity of Hmt1p–Pdi1p is supported by our
in vivo findings that reveal a higher abundance of steady-state
Man7 on ER-retained CPY* than on CPY in wild-type yeast; this
finding suggests that the generation of Man7 is not a passive, uni-
versal event of prolonged ER retention.
The observed preference for partially folded forms can explain
why Htm1p–Pdi1p has higher mannosidase activity against Scr-
CPY than against Carb-CPY. On the other hand, the absence of
ER chaperones to keep CPY* in partially structured states may
explain why Htm1p–Pdi1p is unable to exert its full activity on
CPY* in our in vitro system (44). Because proteins populated at
partially structured states have the propensity to form aggregates
and amyloids (45, 46), this conformational preference of Htm1p–
Pdi1p may ensure that proteins on the verge of aggregating are
promptly committed for degradation. Additionally, this folding
sensitivity of Htm1p–Pdi1p can ensure that nascent, globally un-
folded polypeptides are allowed sufficient time for folding. The
reconstitution system that we have established here provides a
roadmap for future structural investigation of how the recognition
of partially structured proteins is achieved.
A C
B D
Fig. 5. Htm1p–Pdi1p efficiently demannosylates RBsp. (A) Schematic presentation of the generation of RBsp. Native RNase B was treated with subtilisin in a 100:1
ratio at 4 °C for 24 h to generate RNase BS with a nick between the N-terminal S peptide and the rest of the protein (RBsp). RNase BS then was subjected to
precipitation with 10% TCA to remove the soluble S peptide from the precipitated RBsp. (B) Change in the relative abundance ofMan7 on RBsp and native RNase B
during a time-course incubation with Htm1p–Pdi1p. Shown are the mean values ± one SD from an experiment performed in triplicate. (C) Schematic presentation
of the coreaction of RBsp and native RNase B with Htm1p–Pdi1p. RBsp and native RNase B were premixed at a 1:1 ratio, incubated with Htm1p–Pdi1p for 20 min,
and subsequently separated by SDS/PAGE for MS analysis of the individual glycan profiles. (D) Change in the relative abundance of Man7 on premixed RBsp and
native RNase B after incubation with Htm1p–Pdi1p for 20 min. Shown are the mean values ± one SD from an experiment performed in triplicate.
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Interestingly, this conformational preference is reminiscent of that
of UDP-glucose glucosyltransferase (UGGT), which reglucosylates
partially structured proteins to help their retention in the ER folding
cycle (47). The presence of multiple N-glycan–remodeling enzymes
with a similar preference for compact intermediates further argues
for the broad biological importance of detecting partially structured
proteins in the ER. The essential interaction of Htm1p with Pdi1p is
also reminiscent of the predicted structure of UGGT, which contains
three thioredoxin-linked domains that may contribute to peptide
binding (48). Our discovery that Htm1p–Pdi1p can remove the α1,2-
linked mannose from branch C on Man9 without the prior action of
Mns1p suggests a future direction for applying synthetic Man9-gly-
coconjugates that were developed for the investigation of UGGT
(49) for more detailed analysis of how the N-glycan is used as a
potential time indicator by Htm1p–Pdi1p for glycoprotein quality
control in the ER.
To conclude, in addition to the previously characterized
ERAD-L surveillance step mediated by the Yos9p–Hrd3p complex
(6, 7, 16, 50), here we provide evidence for an upstream folding
surveillance step that is mediated by Htm1p–Pdi1p. The presence
of multiple folding surveillance steps, each with its own unique
N-glycan processing or recognition functions, supports a model
in which ERAD-L follows a kinetic proofreading mechanism to
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Fig. 6. 1H-NMR analysis of the glycan released from RNase B before and after
overnight incubation with Htm1p–Pdi1p. (A) Representative N-glycan structures
that cover all potential monosaccharide linkages found on RBsp. The nomen-
clature and peak assignment are based on previous studies (41). (B and C) The
1H-NMR spectra (D2O, 400 MHz) of the glycans released from RBsp before (B)
and after (C) Htm1p–Pdi1p treatment. Note the change in the height of the
peaks corresponding to the α1,6-linked mannose on the C branch with (Bi, blue
arrow) or without (Bt, red arrow) the terminal α1,2-linked mannose (D3) after
incubation with Htm1p–Pdi1p. In contrast, the level of the second α1,2-linked
mannose on the A branch (Ci, purple arrow) did not change after Htm1p–Pdi1p
treatment. Shown is the region covering the H-1 on the anomeric carbon of
each monosaccharide after solvent suppression by the presaturation method.
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Fig. 7. Htm1p–Pdi1p preferentially demannosylates partially structured RNase B
variants. (A) Schematic presentation of the generation of RNase B variants. RNase
BS and RBsp were generated through subtilisin and TCA treatment. Additionally,
RNase B was reductively denatured by DTT in 6 M guanidine hydrochloride and
then was either disulfide-scrambled by diamide to produce Scr-RB or cysteine-
carbamidomethylated by iodoacetamide (IAA) to produce Carb-RB. (B) Circular
dichroism analysis of RNase B variants. (C) The relative abundance of Man7 on
RNase B variants during a time-course incubation with Htm1p–Pdi1p. Shown are
the mean values ± one SD from an experiment performed in triplicate.
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achieve high fidelity in targeting the right proteins for degra-
dation (6, 7, 51).
Materials and Methods
Yeast Strains. All yeast transformations were conducted according to standard
procedures. For chromosomal overexpression ofHTM1 (yJW1819 and yJW1820),
the chromosomal HTM1 locus was deleted from BY4741 by a URA3 selection
marker. Double-stranded DNA starting with either the endogenous 5′ UTR
promoter or a TDH3 promoter for overexpression, followed by the full coding
region of wild-type or mutant HTM1, with a C-terminal 3xFLAG-HDEL tag,
3′ UTR of HTM1, and finally a KANMX selection marker was then introduced
into the htm1Δ::URA3 strain. A pGAL1-MNS1-3xFLAG::KANMX strain (yJW1832)
was generated by the same procedure for the preparation of 3xFLAG-tagged
Mns1p that is controlled by a GAL1 promoter.
Plasmids. The plasmid for GAL1 promoter-driven CPY* expression (pJW1528)
was kindly provided by Tom Rapoport, Harvard Medical School, Boston. To
generate a native CPY expression plasmid (pJW1529), PCR primers carrying the
native G255 codon were used to amplify the G255R region from the CPY* ex-
pression plasmid and then were assembled into the same vector backbone by
the Gibson method. To generate the CPY*0001 expression plasmid (pJW1530),
PCR primers carrying Asn-to-Gln mutations of the first three N-glycosylation sites
were used tomakemutant fragments of CPY* by PCR amplification, which were
assembled into the same 2-μm vector backbone by the Gibson method (52). The
same procedure was used to generate the CPY*1110 plasmid (pJW1609).
Antibodies. Anti-FLAG M2 mouse monoclonal antibody and the antibody-
conjugated agarose beads were purchased from Sigma-Aldrich. Anti-yeast
Pdi1p rabbit antisera was a gift from Peter Walter, University of California, San
Francisco, which was confirmed by recombinantly expressed Pdi1p. IR fluo-
rescence-conjugated secondary antibodies were purchased from LI-COR.
Recombinant Preparation of Htm1p–Pdi1p and Mns1p. The yJW1820 yeast was
grown to the stationary phase in 3 L of yeast extract-peptone-dextrose growth
medium at 30 °C. Cells were harvested by centrifuging at 4,000 × g for 5 min,
washed with cold deionized water, and stored at −80 °C. All the following
purification steps were carried out at 4 °C. Approximately 15 g of cell pellet was
mixed with 5 g of dry ice and then was ground by a Proctor Silex E160BY
grinder for five 30-s on/off cycles. The ground cell was vacuum-degassed for
5 min to remove residual dry ice and was thawed and resuspended in 25 mL of
lysis buffer [20 mM Hepes (pH 7.0), 150 mM NaCl, 2 mM CaCl2, 0.5% (vol/vol)
Nonidet P-40, 15% (vol/vol) glycerol, 1× cOmplete EDTA-free protease inhibitor
mixture (Roche Diagnostics)]. The slurry was centrifuged twice at 6,000 × g to
remove cell debris, nutated for 30 min to solubilize the lipid membrane, and
then ultracentrifuged at 60,000 × g for 30 min. The supernatant was collected
and transferred into a new tube containing an ∼300-μL bed volume of anti-
FLAG M2 affinity agarose beads (Sigma-Aldrich) that had been equilibrated
with the lysis buffer. The mixture was nutated for 3 h and then was transferred
to an open column. The column was washed with 3 mL of wash buffer 1
[20 mM Hepes (pH 7.0), 150 mM NaCl, 2 mM CaCl2, 1× cOmplete EDTA-free
protease inhibitor mixture, 15% (vol/vol) glycerol], 1 mL of wash buffer 2
[20 mM Hepes (pH 7.0), 300 mM NaCl, 2 mM CaCl2, 15% (vol/vol) glycerol], and
1 mL of wash buffer 3 [20 mM Hepes (pH 7.0), 150 mM NaCl, 2 mM CaCl2,
20 mM imidazole, 15% (vol/vol) glycerol]. To release Htm1p–Pdi1p from the
affinity beads, the column was closed by an end-cap, and 10 μg of Tobacco etch
virus (TEV) protease and 300 μL of wash buffer 3 were added. After overnight
incubation without agitation, the cleaved products were eluted with 400 μL of
wash buffer 3. All eluent was collected into a bottom-sealed Micro Bio-Spin
column (Bio-Rad) containing a 100-μL bed volume of Ni-NTA agarose beads
(Qiagen) that had been equilibrated with wash buffer 3. After 30 min of in-
cubation, the spin column was centrifuged at 50 × g for 10 s. The eluent was
collected, and the Ni-NTA beads were further eluted two more times with
100 μL wash buffer 3 for full elution. The eluent was buffer-exchanged into
HSCG buffer [20 mM Hepes (pH 7.0), 150 mM NaCl, 2 mM CaCl2, 15% (vol/vol)
glycerol] on a PD MiniTrap G-25 column (GE Healthcare Life Sciences). Purified
Htm1p–Pdi1pwas stored in aliquots at −80 °C. Endoglycosidase H (New England
Biolabs) treatment was carried out according to the manufacturer’s protocol.
For size-exclusion column chromatography, Htm1p–Pdi1p was eluted with
500 μL of 1 mg/mL 3xFLAG peptide (Sigma-Aldrich) in wash buffer 3 instead of
with TEV protease. The eluent then was loaded and separated in a Superdex
200 10/300 GL column (GE Healthcare Life Sciences) for subsequent Western
blot and mannosidase assays. Protein concentration was determined by Pierce
BCA protein assay (Thermo Fisher Scientific).
For Mns1p preparation, yJW1832 was grown in 3-L dextrose-free yeast/
peptone with 2% (wt/vol) raffinose at 30 °C to the early stationary phase.
Galactose then was added to a final concentration of 2% (wt/vol) to in-
duce expression for 12 h. Then cells were harvested. Cell lysis and affinity
purification were carried with the procedure used for Htm1p–Pdi1p.
Recombinant Preparation of CPY and CPY*. CPY plasmids were introduced into
the desired yeast strain, and the transformed cell was grown in 3-L synthetic
complete (SC)-Leu with 2% (wt/vol) raffinose to an OD600 of 1.0∼1.2. Galactose
was added to a final concentration of 2% (wt/vol) for another 12 h at 30 °C to
induce expression. Cells then were harvested and stored at −80 °C. All the
purification steps were carried out at 4 °C. For CPY*, 15 g of cells were ground
and then resuspended in 25 mL C-lysis buffer [20 mM Hepes (pH 7.0), 500 mM
NaCl, 10 mM imidazole, 10 mM Tris(2-carboxyethyl)phosphine (TCEP)·HCl, 6 M
guanidine hydrochloride, 1% (vol/vol) Nonidet P-40, 1× cOmplete protease in-
hibitor mixture]. The slurry was nutated for 30 min to solubilize the inclusion
body, centrifuged at 6,000 × g for 10 min, and then ultracentrifuged at 60,000 × g
for 30 min. The supernatant was collected and loaded on a Ni-NTA column
containing a 1-mL bed volume of resins that had been equilibrated with C-lysis
buffer. The column was washed with 10 mL C-wash buffer [20 mM Hepes (pH
7.0), 500 mM NaCl, 10 mM imidazole, 10 mM TCEP·HCl, 6 M guanidine hydro-
chloride] and then eluted with C-elution buffer [20mMHepes (pH 7.0), 500 mM
NaCl, 500 mM imidazole, 6 M guanidine hydrochloride]. The eluent was buffer-
exchanged into HSGG buffer [20 mM Hepes (pH 7.0), 150 mM NaCl, 15%
(vol/vol) glycerol, 0.1% (wt/vol) octyl-α-glucopyranoside] and stored at −80 °C
in aliquots.
The purification of native CPY was performed in the same way as CPY*
purification except that guanidine hydrochloride and TCEP·HCl were omitted
from the C-lysis and C-wash buffer, respectively. To make Scr-CPY, CPY was first
reduced with 6 M guanidine hydrochloride and 5 mM DTT at 42 °C for 1 h. N,N,
N′,N′-tetramethylazodicarboxamide (diamide) (Santa Cruz Biotechnology) was
added to a final concentration of 25 mM. The solution was kept at room
temperature for 1 h and then was buffer-exchanged into HSGG buffer. To
make Carb-CPY, CPY was first reduced with 6 M guanidine hydrochloride and
5 mM DTT at 42 °C for 1 h. Then iodoacetamide was added to 25 mM. The
solution was kept at room temperature in the dark for 1 h and thenwas buffer-
exchanged into HSGG buffer. Ellman’s reagent (Sigma-Aldrich) was used to
check the status of cysteines.
Preparation of RNase B. Crude bovine pancreatic RNase B (Sigma-Aldrich) was
first enriched for theMan8GlcNAc2-abundant species. Generally, 50 mg of crude
RNase B was dissolved in EQ buffer [20 mMHepes (pH 7.0), 150mMNaCl, 5 mM
CaCl2, 5 mM MgCl2, 5 mM MnCl2] in a 10 mg/mL concentration and then was
mixed with a 5-mL bed volume of EQ buffer-equilibrated Con A Sepharose
beads (Sigma-Aldrich) at 4 °C for 2 h. The slurry was subsequently transferred
into an open column, washed sequentially with 15 mL EQ buffer, 50 mL high-
salt wash buffer [20 mM Hepes (pH 7.0), 500 mM NaCl, 1 mM CaCl2, 1 mM
MgCl2, 1 mMMnCl2], 10 mL EQ buffer, and finally 200 mL low-Glc wash buffer
[20 mMHepes (pH 7.0), 150 mMNaCl, 50 mMMethyl-α-D-glucopyranoside]. The
column was first eluted with 100 mL of 200-mM-Glc buffer [20 mM Hepes
(pH 7.0), 150 mM NaCl, 200 mM Methyl-α-D-glucopyranoside] into 20 mL per
fraction and was further eluted with 100 mL 1 M Glc buffer [20 mM Hepes
(pH 7.0), 150 mM NaCl, 1 M Methyl-α-D-glucopyranoside]. The N-glycan profile
of RNase B from each step was checked by MALDI-TOFMS. Fractions containing
the desired glycan species were pooled together, adjusted to pH 4.0 by acetic
acid, and then loaded onto a 5-mL HiTrap-SP FF cation-exchange column (GE
Healthcare Life Sciences) that had been equilibrated with acidic buffer [20 mM
Hepes (pH 4.0), 150 mM NaCl]. The cation-exchange column was washed with
25 mL acidic buffer and then was eluted with neutral buffer [20 mM Hepes
(pH 7.0), 500 mM NaCl]. The eluent was buffer-exchanged into HSG buffer
[20 mM Hepes (pH 7.0), 150 mM NaCl, 15% (vol/vol) glycerol] by a PD10 desalting
column (GE Healthcare Life Sciences). Purity was checked by size-exclusion
column chromatography.
For the preparation of RBsp, 1 mg of RNase B was mixedwith 20 μg of freshly
dissolved subtilisin (Sigma-Aldrich) in 2 mL HSG buffer. The mixture was kept at
4 °C overnight, and 20 μg more subtilisin was added for another 1-h incubation
at 4 °C. The pH of the mixture then was adjusted to 2.0 with 1 M hydrochloric
acid for 1 h on ice to destroy subtilisin. Then trichloroacetic acid (TCA) was
added to 10% (wt/vol), and the solution was warmed to room temperature to
allow RBsp precipitation overnight. The mixture was centrifuged at 15,000 × g
for 10 min, and the supernatant was removed. The pellet was dissolved with
9 M deionized urea and then was TCA-precipitated again to remove residual
S-peptide completely. The pellet was dissolvedwith 9M urea, buffer-exchanged
into HSGG buffer, and stored in aliquots at −30 °C. Disulfide-scrambling and
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carbamidomethylation of RNase B and RBsp were carried out with the proce-
dures used for Scr-CPY and Carb-CPY.
Circular Dichroism Analysis. RNase B variantswere buffer-exchanged into 10mM
sodium phosphate (pH 7.0) to a final concentration of 10 μM.Measurement was
conducted on a Jasco J-715 spectrometer in a 1-mm cuvette at 30 °C. The
spectrum was recorded over the range of 190–250 nm at a scanning speed of
20 nm/min with a bandwidth of 1.0 nm.
Limited Proteolysis of RNase B Variants. Trypsin (Sigma-Aldrich) was added to
10 μMRNase B variants to a final concentration of 50 ng/μL at the beginning of
the time-course reaction at room temperature. At each time point, an equal
amount of sample was withdrawn and mixed with 1/10 volume of phenyl-
methylsulfonyl fluoride (Sigma-Aldrich) to stop the reaction for reducing SDS/
PAGE analysis.
PNGase F Sensitivity of RNase B Variants. Glycerol-free PNGase F (New England
Biolabs) was added to 10 μM RNase B variants to a final concentration of
0.5 units/μL at the beginning of the time-course reaction at room temperature.
At each time point, an equal amount of sample waswithdrawn andmixedwith
4× SDS sample buffer to stop the reaction for reducing SDS/PAGE analysis.
Glycan Profiling by MALDI-TOF MS. The procedure for N-glycan profiling by
MALDI-TOF MS was based on published methods (53, 54) with some modifi-
cations. N-glycoproteins were separated by SDS/PAGE and stained by Coomassie
Blue R250. Individual gel bands were excised and destained twice with 100 μL of
50% (vol/vol) acetonitrile with 10 mM Na2CO3 at 50 °C for 30 min with vigorous
shaking. The gels then were reduced by 50 mM DTT in 20 mM Na2CO3 at 50 °C
for 30 min and were alkylated by adding iodoacetamide to a final concentra-
tion of 150mM and incubated in the dark at room temperature for 30 min. The
gels were washed twice by 50% (vol/vol) acetonitrile with 10 mM Na2CO3 at
room temperature for 30 min, dehydrated by 100% acetonitrile at room
temperature for 10 min, and evaporated in a centrifugal evaporator for 10 min.
To each dried gel piece, five units of glycerol-free PNGase F (New England
Biolabs) in 20 μL of 20 mMNa2CO3 were added, and the mixture was incubated
at 37 °C overnight. To extract the released glycans, 100 μL of deionized water
was added, and the mixture was sonicated in the water-bath sonicator for
30 min. The solution was collected, and extraction was repeated two more
times. To desalt the pooled extract, each sample was loaded into a 20-μL filter tip
filled with 10 mg of graphitized carbon (Grace Davidson Discovery Sciences) that
had been sequentially washed with 1 mL of acetonitrile and 1 mL of deionized
water. After the sample was loaded, the tip-column was washed with 1 mL of
deionized water and eluted with 100 μL of 25% (vol/vol) acetonitrile. For free
glycans, the reaction solution was loaded directly onto the graphitized carbon
tip-column and processed with the same procedure. The eluent was evaporated
in the centrifugal evaporator at 60 °C. The dried sample was resuspended with
5 μL of deionized water, and 1 μL of the sample was spotted on the MALDI
target plate and vacuum dried. The plate then was washed with pure aceto-
nitrile. Then 1 μL of 5 mg/mL 2.5-dihydroxybenzoic acid (DHB) (Sigma-Aldrich)
dissolved in 50% (vol/vol) acetonitrile was spotted onto each sample spot and
dried. The mass spectrometric analysis was conducted on a Voyager Elite DE-STR
Pro mass spectrometer (Applied Biosystems) or a Shimadzu AXIMA Perfor-
mance mass spectrometer (Shimadzu) in the positive reflectron mode. For data
collected in the Voyager mass spectrometer, the spectrum analysis was carried
out with the bundled Data Explorer software to extract the area of the peak
matched to each glycan. For spectra collected from the AXIMA Performance
mass spectrometer, raw spectra were exported in the mzXML format and were
analyzed by mMass software (55) to extract the intensity of the peak matched
to each glycan.
Mannosidase Assay. Unless otherwise specified, glycoprotein substrates in the
specified concentration (2 μM for CPY variants, 10 μM for RNase B isoforms)
were mixed with 0.1 μM Htm1p–Pdi1p and/or 0.1 μM Mns1p in reaction buffer
[20 mMHepes (pH 7.0), 150 mM NaCl, 2 mM CaCl2, 0.1% (vol/vol) Nonidet P-40].
At each desired time point, EDTA was added to a final concentration of 25 mM
to stop the demannosylation reaction. The mixture was separated by reducing
SDS/PAGE and then was subjected to N-glycan profiling by MALDI-TOF MS.
NMR Analysis. For the Man8-abundant RNase B control, 2 mg of RNase B was
reduced by 10mMDTT at 95 °C for 10min and thenwas allowed to cool. For the
RBsp treated with Htm1p–Pdi1p, 2 mg of RBsp was first incubated overnight
with 50 μg of Htm1p–Pdi1p. To both samples, 1,000 units of PNGase F were
then added for glycan release at 37 °C overnight. The next day, the reaction
mixture was loaded onto a 200-mg graphitized carbon column, washed with
5 mL of water, and then eluted with 1.5 mL of 25% acetonitrile. The eluent was
lyophilized and then dissolved by D2O (Sigma-Aldrich) for lyophilization two
more times. The dried sample then was dissolved by D2O for NMR measure-
ment. The 1H-NMR was carried out on a 400-MHz Bruker Avance III HD two-
channel instrument with a TopSpin v3.5 interface. Spectra were precollected
using the default proton method, calibrated to the reference chemical shift of
water (4.79 ppm), and then collected with the presaturation method as de-
scribed by the manufacturer to suppress the signal from water.
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